Why Is LNTH Stock Up After Hours?

Lantheus said that the FDA approved its PYLARIFY TruVu injection.

Shares of Lantheus Holdings, Inc. (LNTH) rose 5% after hours on Friday after the company announced that the U.S. Food and Drug Administration has approved its PYLARIFY TruVu injection.

The injection is indicated for imaging certain lesions in men with prostate cancer.

It is now expected to be commercially available in the fourth quarter of 2026.

Get updates to this developing story directly on Stocktwits.<